Pα+ Psychedelic Bulletin #157: Psilocybin for Generalised Anxiety Disorder; Uptick in Psilocybin-Related Poison Centre Calls
- Incannex Shares Topline Results from Phase 2a Study of Psilocybin for Generalised Anxiety Disorder
- Study Design: Benadryl-Assisted Unblinding?
- Efficacy Signal
- Safety Signal
- Next Steps: A Transatlantic Multi-site Phase 2b, But What’s the IP?
- (Psychedelics) Competitive Landscape: LSD and dDMT for GAD
- An Uptick in Psilocybin-Related Poison Centre Calls
- Other News
- Psychedelic Alpha Content You May Have Missed
Companies and candidates mentioned in this Bulletin: Incannex Healthcare, PSX-001, MindMed, MM-120, Cybin, CYB004, Compass Pathways, GH Research, GH001, Enveric Biosciences, atai Life Sciences, aNUma.
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In